Your browser doesn't support javascript.
loading
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.
Tarke, Alison; Ramezani-Rad, Parham; Alves Pereira Neto, Tertuliano; Lee, Yeji; Silva-Moraes, Vanessa; Goodwin, Benjamin; Bloom, Nathaniel; Siddiqui, Leila; Avalos, Liliana; Frazier, April; Zhang, Zeli; da Silva Antunes, Ricardo; Dan, Jennifer; Crotty, Shane; Grifoni, Alba; Sette, Alessandro.
Afiliación
  • Tarke A; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Ramezani-Rad P; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Alves Pereira Neto T; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Lee Y; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Silva-Moraes V; Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
  • Goodwin B; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Bloom N; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Siddiqui L; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Avalos L; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Frazier A; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Zhang Z; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • da Silva Antunes R; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Dan J; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
  • Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: shane@lji.org.
  • Grifoni A; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. Electronic address: agrifoni@lji.org.
  • Sette A; Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: alex@lji.org.
Cell Rep Med ; 5(6): 101583, 2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38781962
ABSTRACT
Little is known about the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or SARS2) vaccine breakthrough infections (BTIs) on the magnitude and breadth of the T cell repertoire after exposure to different variants. We studied samples from individuals who experienced symptomatic BTIs during Delta or Omicron waves. In the pre-BTI samples, 30% of the donors exhibited substantial immune memory against non-S (spike) SARS2 antigens, consistent with previous undiagnosed asymptomatic SARS2 infections. Following symptomatic BTI, we observed (1) enhanced S-specific CD4 and CD8 T cell responses in donors without previous asymptomatic infection, (2) expansion of CD4 and CD8 T cell responses to non-S targets (M, N, and nsps) independent of SARS2 variant, and (3) generation of novel epitopes recognizing variant-specific mutations. These variant-specific T cell responses accounted for 9%-15% of the total epitope repertoire. Overall, BTIs boost vaccine-induced immune responses by increasing the magnitude and by broadening the repertoire of T cell antigens and epitopes recognized.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Linfocitos T CD8-positivos / Epítopos de Linfocito T / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Linfocitos T CD8-positivos / Epítopos de Linfocito T / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos